News

Press releases

April 26, 2022

Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board

January 6, 2022

Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

Media Contact

Rhiannon Jeselonis
rhiannon@tenbridgecommunications.com

In The News

Michael J. Fox Foundation for Parkinson's Research | April 8, 2023

Ambagon and academic collaborators awarded grant from the Michael J Fox Foundation to study 14-3-3:LRRK2 stabilizers as a neuroprotective therapy for Parkinson’s Disease.

BioCentury | January 5, 2023

2022 Class of Emerging Companies

BioSpace | January 4, 2023

Top Life Sciences Startups to Watch in 2023

BioCentury | February 1, 2022

Ambagon: creating molecular glues for disordered proteins

Publications & Presentations

Molecular glues to stabilise protein-protein interactions
Current Opinion in Chemical Biology. 2022.

Macrocycle-stabilization of its interaction with 14-3-3 increases plasma membrane localization and activity of CFTR
Nat Commun. 2022.

Reversible Covalent Imine-tethering for Selective Stabilization of 14-3-3 Hub Protein Interactions
J. Am. Chem. Soc. 2021

Fragment-based Differential Targeting of PPI Stabilizer Interfaces
J. Med. Chem. 2020

Structure-based Evolution of a Promiscuous Inhibitor to a Selective Stabilizer of Protein–protein Interactions
Nat Commun. 2020

Site-directed Fragment-Based Screening for the Discovery of Protein–protein Interaction Stabilizers.
J. Am. Chem. Soc. 2019

Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers
ACS Chem Biol. 2013